Formulation, Development and Characterization of Effective    Niosomal Drug Delivery System for the Treatment of Diabetes Mellitus

Nida Musheer; Vivek Gupta

doi:10.24092/CRPS.2020.100402

Nida Musheer Shri Rawatpura Sarkar Institute of Pharmacy, Datia, Madhya Pradesh, India
Vivek Gupta Shri Rawatpura Sarkar Institute of Pharmacy, Datia, Madhya Pradesh, India

DOI https://doi.org/10.24092/CRPS.2020.100402

Abstract

In the present study, gliclazide-loaded niosomes are formulated and evaluated for their in vitro as well as in vivo characteristic in an attempt to improve the oral bioavailability of the drug. Formulation of niosomes was optimized for highest percentage of drug entrapment. Microscopic observation confirmed that all particles were uniform in size and shape. The entrapment efficiency was determined by separating the unentrapped drug using dialysis. The in vitro release studies of drug from niosomes exhibited a prolonged drug release as observed over a period of 24 h. The positive values of zeta potential indicated that the gliclazide niosomes were stabilized by electrostatic repulsive forces. Results from stability study have shown that the drug leakage from the vesicles was least at 4ºC followed by 25 and 37ºC. The niosomes showing maximum entrapment and suitable release rate were selected for in vivo evaluation. In conclusion, the niosomal formulation could be a promising delivery system for gliclazide with improved bioavailability and prolonged drug release profile.

Keywords: Heme Oxygenase Inhibitor, HO-1, 2D QSAR, 3D QSAR, kNN-MFA

References

1. Ladbrooke BD, Williams RM, Chapman D. Studies on lecithin-cholesterol-water interaction by differential scanning calorimetry andX-ray diffraction. Biochim Biophys Acta, 1968; 150:333–40.
2. Trinder P. Determination of glucose in blood using glucoseoxidase with an alternative oxygen acceptor. Ann Clin Biochem, 1969; 6:24–7.
3. Lebacq EG, Tirzmalis A. Metformin and lactic acidosis. Lancet, 1:314–15.
4. Papahadjopoulos D, Jacobson K, Nir S, Isac T. Phase transitionsin phospholipid vesicles: fluorescence polarization and permeabilityproperties concerning the effect of temperature and cholesterol.Biochim Biophys Acta, 1973; 311:330–48.
5. Finkelstein MC, Weissman G. Enzyme replacement vialiposomes. Int J Pharm, 1979; 588:202–16.
6. Vidon N, Chaussade S, Noel M, et al. Metformin in the digestivetract, diabetes. Res Clin Pract, 1988; 4:223–9.
7. Betageri GV, Parsons DL. Drug encapsulation and release frommultilamellar and unilamellar liposomes. Int J Pharm, 1992 81:235–41
8. Hermann LS, Melander A. (1992). Biguanides: basic aspects and clinicaluse. In: Alberti KGMM, De Fronzo RA, Keen H, eds. Internationaltextbook of diabetes mellitus. New York: Wiley, 1992; 772–95.
9. Khandare JN, Madhavi G, Tamhankar BM. (1994). Niosomes novel drugdelivery system East Pharm, 1994; 37:61–4.
10. Raja Naresh RA, Chandrashekhar G, Pillai GK, Udupa N. (1994).Anti-inflammatory activity of niosome encapsulated diclofenacsodium with Tween-85 in Arthitic rats. Indian J Pharmacol, 1994; 26:46–8.
11. Yoshioka T, Sternberg B, Florence AT. (1994). Preparation andproperties of vesicles (niosomes) of sorbitan monoesters (Span-20,40, 60 and 80) and sorbitan triester (Span 85). Int J Pharm, 1994; 105:1–6.
12. Popli H, Nair MS. (1996). Niosomal delivery of tenoxicam. Indian JPharm Sci, 1996; 58:163–6.
13. Scheen AJ. Clinical pharmacokinetics of metformin. ClinPharmacokinet, 1996; 30:359– 71.
14. Van Hal DA, Bouwstra JA, Rensen AV. Preparation andcharacterization of non-ionic surfactant vesicles. J Colloid InterfaceSci, 1996; 178:263–73.
15. Omaima NE, Ahmed HH. Formulation and evaluation ofacetazolamide liposomes as an ocular drug delivery system. Int JPharm, 1997; 158:121–7.
16. Carafa M, Santucci E, Alhaique F. “Preparation andproperties of new unilamellar non- ionic/ionic surfactant vesicles”. Int J Pharm, 1998; 160:51–9.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications inoverweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998; 352:854–65.
18. Vyas SP, Mysore N, Jaitely V, Venkatesan N. Discoidal niosomebased controlled ocular delivery of timolol maleate. Pharmazie, 1998; 53:466–9.
19. Chengjiu H, David Rhodes G:Proniosomes: A Novel Drug CarrierPreparation.Int J Pharm, 1999; 185:23–35.
20. Namdeo A, Jain NK. Niosomal delivery of 5-flurouracil. J MicroEncapsul, 19999; 16:731–40.
21. El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanideinhibits cell respiration via an indirect effect targeted on therespiratory chain complex I. J Biol Chem, 2000; 275:223–8.
22. Owen MR, Doran E, Halestrap AP. Evidence that metforminexerts its anti-diabetic effects through inhibition of complex 1 of themitochondrial respiratory chain. Biochem J, 2000; 348:607–14.
23. Sihorkar V, Vyas SP. Polysaccharide coated niosomes for oral drug delivery:formulation and in vitro stability studies. Pharmazie, 2000; 55:107–13.
24. West JL, Halas NJ. Applications of nanotechnology to biotech-nology commentary. Curr Opin Biotechnol, 2000; 1:215–17.
25. Fang J, Hong CT, Chiu W, Wang YY. Effect of liposomes andniosomes on skin permeation of enoxacin. Int J Pharm, 2001; 219:61–72.